Oruka Therapeutics, Inc.
ORKA
$10.45
$0.171.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 59.73% | 33.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.19% | 37.02% | |||
| Operating Income | -27.19% | -37.02% | |||
| Income Before Tax | -16.66% | -28.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.66% | -28.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.66% | -28.68% | |||
| EBIT | -27.19% | -37.02% | |||
| EBITDA | -27.14% | -- | |||
| EPS Basic | 62.93% | 96.94% | |||
| Normalized Basic EPS | 61.11% | 96.00% | |||
| EPS Diluted | 62.93% | 96.94% | |||
| Normalized Diluted EPS | 61.11% | 96.00% | |||
| Average Basic Shares Outstanding | 192.14% | 3,119.06% | |||
| Average Diluted Shares Outstanding | 192.14% | 3,119.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||